I think you were looking into the future at 2HY 2016 results when predicting $25M NPAT for 1HY 2016.
The highlight of this update is the huge increase in margin compared to the 2 previous HYs. This is when only 1 month out of 6 reflected the product price increase.
Margins for 2HY2016 will surely be at a minimum 25+%. They are also expecting revenue in 2HY 2016 to be stronger than 1HY2016.
It's realistic that EBIT for 2HY2016 could be $150M. That would mean EBIT of $37.5M at 25% margin. Even that is being on the conservative side - i.e. assuming only 50% revenue growth on 1HY2016.
FY 2016 EDIT of $56.5M (19 + 37.5) or NPAT of $40M. At $12.80, that's a P/E of ~31.
That's still a "buy" for a company that has just reported a 430% increase for EBIT on the PCP (prior corresponding period - i.e. 1FY2015).
BAL Price at posting:
$12.80 Sentiment: Buy Disclosure: Held